Board changes - Replacement
CelLBxHealth PLC has amended a previous announcement regarding board changes, adding that Non-Executive Director Klaas de Boer holds 2,002,319 ordinary shares, representing approximately 0.18% of the company's issued share capital. This amendment follows the appointments of Peter Collins as Chief Executive Officer and Klaas de Boer, Kim Oreskovic, and Benjamin Hart as Non-Executive Directors, while Joseph Eid steps down from the board. The company, a leader in circulating tumour cell intelligence, aims to leverage the expertise of its new board members to focus on strategic opportunities and deliver long-term shareholder value.
Select text to share a quote on X · sign in to keep highlights & notes in your CLBX notes
The following amendment has been made to the 'Board changes' announcement released on 12 January 2026 at 7:00 a.m. under RNS No 4265O.
Addition of "Klaas De Boer holds an interest in 2,002,319 ordinary shares in CelLBxHealth plc which represents an approximately 0.18% holding of the Company's issued share capital."
All other details remain unchanged.
The full amended text is shown below.
CelLBxHealth plc (the "Company")
Board changes
Guildford, UK and Plymouth Meeting, US - CelLBxHealth plc (AIM: CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug development and clinical oncology, is pleased to announce that further to the announcement of 15 December 2025, that the following have been appointed to the board with immediate effect:
- Peter Collins as Chief Executive Officer
- Klaas de Boer as Non-Executive Director
- Kim Oreskovic as Non-Executive Director
- Benjamin Hart as Non-Executive Director
The information required in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies is detailed at the end of this announcement.
Separately Non-Executive Director, Joseph Eid will step down from the board, effective 31 January 2026.
Jan Groen, Executive Chair of CelLBxHealth plc, said: "We welcome Peter and the non-executives to the board. Their extensive expertise, combined with additional life sciences experience will significantly enhance the board's capabilities as we focus on strategic opportunities and delivering long-term shareholder value. We would also like to thank Joseph for his assistance over his tenure and wish him all the best for the future."
AIM Rules Schedule 2 (g) information
The directorships and partnerships currently held by Peter Michael Collins, aged 67, and over the five years preceding the date of this announcement are as follows:
| Current directorships | Previous directorships held in the past five years |
Saga Diagnostics UK Limited SAGA Diagnostics AB Collins Biotech Consulting SRL
The directorships and partnerships currently held by Klaas De Boer, aged 60, and over the five years preceding the date of this announcement are as follows:
| Current directorships | Previous directorships held in the past five years |
| Tsjukemar Ltd General Fusion Inc Xeros Technology Group plc SmartKem Inc Smartkem Ltd Fashion for Good BV | Entrepreneurs Fund Management LLP Entrepreneurs Fund Management Services Ltd veriNOS Pharmaceuticals GmbH (Previously known as vasopharm GmbH) Stichting Administratiekantoor Bellevue |
Klaas De Boer holds an interest in 2,002,319 ordinary shares in CelLBxHealth plc which represents an approximately 0.18% holding of the Company's issued share capital.
The directorships and partnerships currently held by Benjamin Jacob Hart, aged 38, and over the five years preceding the date of this announcement are as follows:
| Current directorships | Previous directorships held in the past five years |
Applied Technology Partners LLC
The directorships and partnerships currently held by Kimberley Anne Oreskovic, aged 60, and over the five years preceding the date of this announcement are as follows:
| Current directorships | Previous directorships held in the past five years |
Innoviance Investments B.V. Innoviance Consulting B.V.
There are no further disclosures required under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.